Embarc Benefit Protection℠ – Affordability and access that can literally save lives
Embarc Benefit Protection
This novel solution addresses the critical need facing everyone from payers to patients by delivering better care, affordability and access. As the industry’s first solution to build a new pathway to pay for the coming wave of expensive, potentially curative therapies, Embarc Benefit Protection will change the future of health care.
In the Embarc Benefit Protection solution, we will include Luxturna® (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease, and Zolgensma® (onasemnogene abeparvovec-xioi), a gene therapy for children under 2 years old with spinal muscular atrophy. As new gene and cell therapies are approved by the FDA, we will evaluate for future inclusion.
Together, the path is clear
Like our Patient Assurance Program℠ and Digital Health Formulary, Embarc Benefit Protection demonstrates what our combined company can do for our clients and patients to deliver on the promise of modern medicine. Our goal is to help make these life-changing, high-cost gene therapies accessible to the people who need them – as soon as possible.
Explore related insights